The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications

Respiratory Medicine

Volumn 93, Issue 1, 1999, Pages 52-57

  Poulakis, N ^a,c   Androutsos, G ^b   Kazi, D ^a   Bastas, A ^a   Provata, A ^a   Bitsakou, C ^a   Kontozoglou, T ^a   Polyzogopoulou, C ^a   Tassiopoulou, A ^b  

^a Athens Chest Dis Hospital 'Sotiria'   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PENTOXIFYLLINE; PERIPHERAL VASODILATING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; MALE; MONOCYTE; PRIORITY JOURNAL; SUPERNATANT;

EID: 0032945865     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(99)90077-X     Document Type: Article

References (34)

1. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990; 141: 471-501.
2. Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990; 141: 765-788.
3. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264: 713-716.
4. Baldwin GC. The biology of granulocyte-macrophage colony-stimulating factor: effects of hematopoietic and nonhematopoietic cells. Devl Biol 1992; 151: 352-367.
5. Nakata K, Akagawa S, Fukayama M, et al. Granulocyte-macrophage colony-stimulating factor promotes the proliferation of human alveolar macrophages in vitro, J Immunol 1991; 147: 1266-1272.
6. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/ macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U.S.A. 1994; 91: 5592-5596.
7. Xing Z, Braciak T, Ohkawara Y, et al. Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. J Leukoc Biol 1996; 59: 481-488.
8. Tilg H, Dinarelo CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 1997; 18: 428-432.
9. Ward A, Clissold SP. Pentoxiphylline: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 1987; 34: 40-97.
10. Seiffge D, Bissinger T, Kremer E, et al. Inhibitory effects of pentoxifylline on LPS induced leukocyte adhesion and macromolecular extravasation in the microcirculation. Inflamm Res 1995; 44: 281-286.
11. Lauterbach R, Zembala M. Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr 1996; 155: 404-409.
12. Zeni F, Pain P, Vindimian M, et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996; 24: 207-214.
13. Zabel P, Schonharting MM, Schade UF, Schlaak M. Effects of pentoxifylline in endotoxinemia in human volunteers. Prog Clin Biol Res 1991; 367: 207-213.
14. Chapelier A, Reignier J, Mazmanian M, et al. Pentoxifylline and lung ischemia-reperfusion injury: application to lung transplantation. Universite Paris Sud Lung Transplant Group. Cardiovasc Pharmacol 1995; 25 (Suppl. 2): S130-S133.
15. Marques LJ, Poulakis N, Zheng L, et al. Pentoxiphylline inhibits TNF-a production by human alveolar macrophages. Eur Respir J 1995; 8 (Suppl. 19): s339.
16. Balibrea JL, Arias Diaz J, Garcia C, Vara E. Effect of pentoxifylline and somatostatin on tumour necrosis factor production by human pulmonary macrophages. Circ Shock 1994; 43: 51-56.
17. Bienvenu J, Doche C, Gutowski MC, et al. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995; 25 (Suppl. 2): S80-S84.
18. Steffen M, Petersen J, Oldigs M, et al. Increased secretion of tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol 1993; 91: 939-949.
19. Wewers MD, Herzyk DJ. Alveolar macrophages differ from blood monocytes in human IL-1 beta release. Quantitation by enzyme-linked immunoassay. J Immunol 1989; 143: 1635-1641.
20. Semmler J, Gebert U, Eisenhut T, et al-. Zanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 1993; 78: 520-525.
21. Bernard C, Barnier P, Merval R, et al. Pentoxifylline selectivity inhibits tumor necrosis factor synthesis in the arterial wall. J Cardiovasc Pharmacol 1995; 25 (Suppl. 2): S30-S33.
22. Torphy TJ, Murray KJ, Arch JRS. Selective phosphodiesterase isozyme inhibitors. In: Page CP, Metzger WJ, eds. Drugs and the Lung. New York: Raven Press, 1994, 397-447.
23. Tenor H, Hatzelmann A, Kupferschmidt R, et al. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 1995; 25: 625-633.
24. Strieter RM, Remick DG, Ward PA, et al Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-1236.
25. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/ tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-394.
26. Tsujino A, Nakamura T, Nishiura Y, et al. Pentoxifylline down-regulates adhesion molecule expression and inflammatory cytokine production in cultured peripheral blood mononuclear cells from patients with HTLV I associated myelopathy. J Neuroimmunol 1997; 73: 191-196.
27. Heinkelein M, Schneider-Schaulies J, Walker BD, et al. Inhibition of cytotoxicity and cytokine release of CD8+HIV specific cytotoxic T lymphocytes by pentoxifylline. J Acq Immune Def Syndr Hum Retrovirol 1995; 10: 417-424.
28. Strieter RM, Remick DG, Lynch JP, et al. Differential regulation of tumor necrosis factor-alpha in human alveolar macrophages and peripheral blood monocytes: a cellular and molecular analysis. Am J Respir Cell Mol Biol 1989; 1: 57-63.
29. Standiford TJ, Kunkel SL, Rolfe MW, et al. Regulation of human alveolar macrophage and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am J Respir Cell Mol Biol 1992; 6: 75-81.
30. Belloc F, Jaloustre C, Dumain P, et al. Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol 1995; 25 (Suppl. 2): S71-S74.
31. Roberts PJ, Yong KL, Khwaja A, et al. Pentoxifylline at clinically achievable levels inhibits FMLP-induced neutrophil responses, but not priming, upregulation of cell-adhesion molecules, or migration induced by GM-CSF. Eur J Haematol 1993; 50: 1-10.
32. Mandell GL. Cytokines, phagocytes, and pentoxifylline. J Cardiovasc Pharmacol 1995; 25 (Suppl. 2): S20-S22.
33. Sourbier P, Perianin A, Hakim J. In vitro effect of pentoxifylline human neutrophil function. In: Mandell GL, Novick WJ Jr, eds. Pentoxifylline and Leukocyte Function. Somerville, NY: Hoechst Roussel Pharmaceutical, 1989, 56-67.
34. Lilly CM, Sandhu JS, Ishizaka A, et al. Pentoxifylline prevents tumor necrosis factor induced lung injury. Am Rev Respir Dis 1989; 139: 1361-1368.